Benjamin H. Lowentritt, MD, FACS

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.

Benjamin H. Lowentritt, MD, FACS, provides clinical insights on the use of different formulations of abiraterone as treatment for patients with prostate cancer.

In the first article of this series, Benjamin H. Lowentritt, MD, FACS, gives an overview of micronized abiraterone and its role in the treatment of patients with metastatic castrate-resistant prostate cancer.

Benjamin H. Lowentritt, MD, FACS, shares background information on micronized abiraterone and discusses its role in the evolving prostate cancer treatment landscape.

In the third interview of the series, Benjamin H. Lowentritt, MD, FACS, reflects on financial and operational considerations in the use of leuprolide with emphasis on managing the cost burden, coding and reimbursement, and product inventory.

A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.

Current limitations of real-world data available that support the use of novel therapies, including androgen receptor inhibitors, as treatment for advanced prostate cancer.

In response to a presentation from AUA 2021, Dr. Julie N. Graff considers the role of PSA kinetics as prognostic markers in advanced prostate cancer.

Based on long-term data and clinical experience treating advanced prostate cancer with androgen receptor inhibitors, Drs Julie N. Graff and Benjamin H. Lowentritt suggest ideas for future study.

Considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.

Julie N. Graff, MD, highlights the efficacy associated with the use of androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer.

Various factors that medical oncologists consider when selecting to treat metastatic castration-sensitive prostate cancer with either apalutamide or enzalutamide.

Julie N. Graff, MD, of OHSU Knight Cancer Institute, comments on the impact of the availability of newer-generation androgen receptor inhibitors on treatment outcomes for patients with advanced prostate cancer.

The role of urologists in working with medical oncologists to treat patients with advanced prostate cancer, with special considerations for early referral.